Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis

In brief

The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in pediatric participants with new onset Pseudomonas aeruginosa respiratory tract infection or colonization.

Key facts

Study ID
NCT03219164
Run by
Gilead Sciences
People needed
149
Starts
2017-11-28
Expected to finish
2021-09-23
Last updated by the study team
2022-06-14

Who can join

Age: 0 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.